While the optimum cut off value varies significantly in published literature on patients with HCC treated with TACE, it has been suggested that higher pre-treatment AFP is associated with earlier recurrence and poorer overall survival [23–25]. This evidence concerns the gene AFP and hepatocellular carcinoma.